RecruitingPhase 1Phase 2NCT05850234

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

A Phase Ib/II Study of AZD0120, Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against CD19 and B-cell Maturation Antigen (BCMA) in Participants With Relapsed/Refractory Multiple Myeloma (DURGA-1)

Sponsor

AstraZeneca

Enrollment

182 participants

Start Date

Jul 20, 2023

Study Type

INTERVENTIONAL

Conditions

Relapsed/Refractory Multiple Myeloma

Summary

This trial is a Phase 1b/2, open-label, multicenter study of AZD0120, a CD19/BCMA dual CAR T-cell therapy, in adult subjects with relapsed/refractory multiple myeloma.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing GC012F (also known as AZD0120), a CAR-T cell therapy that targets two proteins found on myeloma cells (CD19 and BCMA), in people with multiple myeloma that has come back or stopped responding to multiple prior treatments. This dual-targeting approach may overcome resistance that single-target therapies face. **You may be eligible if...** - You are 18 or older - You have a confirmed diagnosis of multiple myeloma - You have received at least three previous treatment regimens, including both a proteasome inhibitor and an immunomodulatory drug (IMiD) - You are in reasonably good health (ECOG score 0 or 1) **You may NOT be eligible if...** - You have previously received a BCMA-targeted therapy that includes this same type of approach - You have active, serious infections - You have significant heart, liver, or lung problems - You are pregnant or breastfeeding - Your myeloma has spread to the brain or spinal cord Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALAZD0120

AZD0120 is a BCMA/CD19 dual CAR T product under investigation for the treatment of participants with RRMM.

Locations(36)

Research Site

Birmingham, Alabama, United States

Research Site

Phoenix, Arizona, United States

Research Site

La Jolla, California, United States

Research Site

Los Angeles, California, United States

Research Site

San Francisco, California, United States

Research Site

Aurora, Colorado, United States

Research Site

Denver, Colorado, United States

Research Site

Jacksonville, Florida, United States

Research Site

Miami, Florida, United States

Research Site

Tampa, Florida, United States

Research Site

Atlanta, Georgia, United States

Research Site

Chicago, Illinois, United States

Research Site

Iowa City, Iowa, United States

Research Site

Boston, Massachusetts, United States

Research Site

Boston, Massachusetts, United States

Research Site

Ann Arbor, Michigan, United States

Research Site

Detroit, Michigan, United States

Research Site

Minneapolis, Minnesota, United States

Research Site

Rochester, Minnesota, United States

Research Site

Omaha, Nebraska, United States

Research Site

Hackensack, New Jersey, United States

Research Site

Buffalo, New York, United States

Research Site

New York, New York, United States

Research Site

Stony Brook, New York, United States

Research Site

Charlotte, North Carolina, United States

Research Site

Durham, North Carolina, United States

Research Site

Nashville, Tennessee, United States

Research Site

Nashville, Tennessee, United States

Research Site

Austin, Texas, United States

Research Site

Dallas, Texas, United States

Research Site

Houston, Texas, United States

Research Site

Salt Lake City, Utah, United States

Research Site

Charlottesville, Virginia, United States

Research Site

Edmonds, Washington, United States

Research Site

Seattle, Washington, United States

Research Site

Milwaukee, Wisconsin, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05850234

Related Trials

Autologous Chimeric Antigen Receptor (CAR) T-cells Targeting the Kappa Myeloma Antigen (KMA) in Kappa Restricted Multiple Myeloma Patients With Relapsed/Refractory Disease

NCT075413911 location

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

NCT0497360584 locations

A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT0516058487 locations

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

NCT07391657111 locations

A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT066692477 locations